Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
130
NCT03892096
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Phase: N/A
Role: Lead Sponsor
Start: Mar 1, 2019
Completion: Feb 6, 2024